OTCPK:VICA

Stock Analysis Report

Executive Summary

Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Rafina Innovations's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.2%

VICA

4.6%

US Healthcare

2.3%

US Market


1 Year Return

n/a

VICA

-8.5%

US Healthcare

5.6%

US Market

Return vs Industry: Insufficient data to determine how VICA performed against the US Healthcare industry.

Return vs Market: Insufficient data to determine how VICA performed against the US Market.


Shareholder returns

VICAIndustryMarket
7 Day-8.2%4.6%2.3%
30 Day9.1%-0.1%-1.0%
90 Day-4.2%-4.5%-0.7%
1 Yearn/a-7.1%-8.5%7.9%5.6%
3 Year-99.4%-99.4%31.9%26.5%45.6%36.3%
5 Year-98.2%-98.2%63.7%53.9%65.8%47.6%

Price Volatility Vs. Market

How volatile is Rafina Innovations's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Rafina Innovations undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Rafina Innovations is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Rafina Innovations has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VICA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Rafina Innovations regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Rafina Innovations forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

10.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Rafina Innovations has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of VICA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Rafina Innovations's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Rafina Innovations performed over the past 5 years?

26.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VICA is unprofitable, but has reduced losses over the past 5 years at a rate of 26.8% per year.

Accelerating Growth: Unable to compare VICA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VICA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: VICA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: VICA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VICA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Rafina Innovations's financial position?


Financial Position Analysis

Short Term Liabilities: VICA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: VICA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: VICA has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: VICA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: VICA has a high level of physical assets or inventory.

Debt Coverage by Assets: VICA has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VICA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: VICA has less than a year of cash runway if free cash flow continues to grow at historical rates of 5% each year.


Next Steps

Dividend

What is Rafina Innovations's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VICA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VICA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VICA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VICA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VICA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Rafina Innovations's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Constantinos Zertalis (41yo)

1yrs

Tenure

US$909,670

Compensation

Mr. Constantinos Zertalis has been Chief Executive Officer, President and Director of Rafina Innovations Inc since October 3, 2018. He has been Chairman of Rafina Innovations Inc. since October 19, 2018. S ...


Management Age and Tenure

1.3yrs

Average Tenure

43yo

Average Age

Experienced Management: VICA's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Age and Tenure

1.3yrs

Average Tenure

42yo

Average Age

Experienced Board: VICA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Nikolaos Kardaras (69yo)

    Head of Legal Department

    • Tenure: 0yrs
  • Stephan Solomonidis

    Head of Research

    • Tenure: 5.5yrs
  • Yiannis Levantis (43yo)

    Technology Advisor & Director

    • Tenure: 4.3yrs
  • Evaggelia Moschidou

    Marketing Director

    • Tenure: 4.1yrs
  • Georgios Thrapsaniotis (74yo)

    Treasurer & Director

    • Tenure: 1.7yrs
  • Constantinos Zertalis (41yo)

    Chairman

    • Tenure: 1yrs
    • Compensation: US$909.67k
  • Paraskevi Pilarinou

    Financial Controller

    • Tenure: 0yrs
    • Compensation: US$548.82k
  • Paraskevi Pylarinou (31yo)

    CFO, Secretary & Director

    • Tenure: 1yrs
  • Hari Elangovan

    Acting Chief Technology Officer

    • Tenure: 0.9yrs

Board Members

  • Yiannis Levantis (43yo)

    Technology Advisor & Director

    • Tenure: 4.3yrs
  • Georgios Thrapsaniotis (74yo)

    Treasurer & Director

    • Tenure: 1.7yrs
  • Constantinos Zertalis (41yo)

    Chairman

    • Tenure: 1yrs
    • Compensation: US$909.67k
  • Paraskevi Pylarinou (31yo)

    CFO, Secretary & Director

    • Tenure: 1yrs

Company Information

Rafina Innovations Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rafina Innovations Inc.
  • Ticker: VICA
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$1.905m
  • Shares outstanding: 17.28m
  • Website: https://rafina-innovations.com

Number of Employees


Location

  • Rafina Innovations Inc.
  • Kintyre House
  • 209 Govan Road
  • Glasgow
  • G51 1HJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VICAOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 2008

Biography

Rafina Innovations Inc. engages in the research, development, commercialization, and marketing of medical technologies. It operates through two segments, Clinics and Technology. The company also operates p ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:06
End of Day Share Price2019/10/15 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.